Secondary prevention of Alzheimer’s dementia: neuroimaging contributions

[1]  Sterling C. Johnson,et al.  In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls , 2018, The Journal of Nuclear Medicine.

[2]  A. Fagan,et al.  Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging , 2018, Alzheimer's & Dementia.

[3]  Keith A. Johnson,et al.  Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing , 2018, Brain : a journal of neurology.

[4]  G. Frisoni,et al.  Clinical utility of FDG-PET for the clinical diagnosis in MCI , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  D. Rujescu,et al.  Amyloid blood biomarker detects Alzheimer's disease , 2018, EMBO molecular medicine.

[6]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[7]  B. Christian,et al.  In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer’s disease dementia to young controls , 2018, bioRxiv.

[8]  Christopher G Schwarz,et al.  Longitudinal tau PET in ageing and Alzheimer’s disease , 2018, Brain : a journal of neurology.

[9]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[10]  O Almkvist,et al.  Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia , 2018, Molecular Psychiatry.

[11]  J. Sepulcre,et al.  In vivo staging of regional amyloid deposition , 2017, Neurology.

[12]  C. Rowe,et al.  A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study , 2017, Alzheimer's & dementia.

[13]  J. Götz,et al.  Tau-based therapies in neurodegeneration: opportunities and challenges , 2017, Nature Reviews Drug Discovery.

[14]  M. Mintun,et al.  Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials , 2017, Alzheimer's & Dementia.

[15]  S. Bachurin,et al.  Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends , 2017, Medicinal research reviews.

[16]  Simon Cervenka,et al.  In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings , 2017, Ageing Research Reviews.

[17]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[18]  Pieter Jelle Visser,et al.  Brain Amyloid Pathology and Cognitive Function: Alzheimer Disease Without Dementia? , 2017, JAMA.

[19]  Christopher C Rowe,et al.  Biochemically-defined pools of amyloid-&bgr; in sporadic Alzheimer’s disease: correlation with amyloid PET , 2017, Brain : a journal of neurology.

[20]  F. Barkhof,et al.  Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET , 2017, European Radiology.

[21]  J. Kaye,et al.  Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility , 2017, Alzheimer's & Dementia.

[22]  Jorge Sepulcre,et al.  Fluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline , 2017, Annals of neurology.

[23]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[24]  Eleni Sakka,et al.  Integrity of normal-appearing white matter: Influence of age, visible lesion burden and hypertension in patients with small-vessel disease , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  Craig W. Ritchie,et al.  Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project , 2017, Alzheimer's & Dementia.

[26]  Massimo Filippi,et al.  The European DTI Study on Dementia — A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment , 2017, NeuroImage.

[27]  Stefan Klöppel,et al.  Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects. , 2016, Journal of Alzheimer's disease : JAD.

[28]  W. M. van der Flier,et al.  Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline , 2016, Alzheimer's & dementia.

[29]  Jieqing Jiao,et al.  ASL-incorporated Pharmacokinetic Modelling of PET Data With Reduced Acquisition Time: Application to Amyloid Imaging , 2016, MICCAI.

[30]  D. Hill,et al.  Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration , 2016, Neurology.

[31]  J. Thiran,et al.  Basic MR sequence parameters systematically bias automated brain volume estimation , 2016, Neuroradiology.

[32]  C. Rowe,et al.  Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study , 2016, The Lancet Neurology.

[33]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[34]  Simon Duchesne,et al.  Normative data for subcortical regional volumes over the lifetime of the adult human brain , 2016, NeuroImage.

[35]  K. Blennow,et al.  Alzheimer's disease , 2016, The Lancet.

[36]  Philip S. Insel,et al.  Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information , 2016, Alzheimer's & dementia.

[37]  A. Hofman,et al.  Association of Cerebral Microbleeds With Cognitive Decline and Dementia. , 2016, JAMA neurology.

[38]  L. Baker.  EXERCISE AND MEMORY DECLINE , 2016, Alzheimer's & Dementia.

[39]  M. Carrillo,et al.  FROM THE WHO RESEARCH PRIORITIES AND RESEARCH PORTFOLIO ANALYSIS TO THE IDENTIFICATION OF RESEARCH GAPS TO REDUCE THE GLOBAL BURDEN OF DEMENTIA , 2016, Alzheimer's & Dementia.

[40]  David Manset,et al.  Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease , 2016, Psychiatry Research: Neuroimaging.

[41]  O. Hansson,et al.  18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers , 2016, Brain : a journal of neurology.

[42]  Ludovico Minati,et al.  Test‐retest reliability of the default mode network in a multi‐centric fMRI study of healthy elderly: Effects of data‐driven physiological noise correction techniques , 2016, Human brain mapping.

[43]  Nick C Fox,et al.  White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network , 2016, Annals of neurology.

[44]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[45]  Matthias L. Schroeter,et al.  Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  M. Lubberink,et al.  Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  Giovanni Giulietti,et al.  Longitudinal Changes in Functional Brain Connectivity Predicts Conversion to Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[48]  E. Siemers,et al.  Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease , 2016, Alzheimer's & dementia.

[49]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[50]  O. Hansson,et al.  Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography , 2016, Brain : a journal of neurology.

[51]  José Luis Molinuevo,et al.  Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. , 2016, The lancet. Psychiatry.

[52]  Abhay Moghekar,et al.  Cortical thickness in relation to clinical symptom onset in preclinical AD , 2016, NeuroImage: Clinical.

[53]  D G Norris,et al.  Diffusion tensor imaging of the hippocampus predicts the risk of dementia; the RUN DMC study , 2016, Human brain mapping.

[54]  Ludovico Minati,et al.  Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study , 2016, NeuroImage.

[55]  Cindee M. Madison,et al.  Effects of Beta-Amyloid on Resting State Functional Connectivity Within and Between Networks Reflect Known Patterns of Regional Vulnerability. , 2014, Cerebral cortex.

[56]  L. Wahlund,et al.  Cerebral microbleeds as a biomarker in Alzheimer's disease? A review in the field. , 2016, Biomarkers in medicine.

[57]  C. Jack,et al.  Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. , 2016, JAMA neurology.

[58]  Leo Joskowicz,et al.  Medical Image Computing and Computer-Assisted Intervention – MICCAI 2016 , 2016, Lecture Notes in Computer Science.

[59]  G. Chételat,et al.  Structural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease , 2015, Neuroscience.

[60]  Matthew L Senjem,et al.  Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings , 2015, Brain : a journal of neurology.

[61]  Lennart Thurfjell,et al.  The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.

[62]  G. Chételat,et al.  Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease , 2015, The Journal of Neuroscience.

[63]  Charles DeCarli,et al.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.

[64]  Nick C Fox,et al.  Diffusion imaging changes in grey matter in Alzheimer’s disease: a potential marker of early neurodegeneration , 2015, Alzheimer's Research & Therapy.

[65]  Yi Wang,et al.  Multi-vendor reliability of arterial spin labeling perfusion MRI using a near-identical sequence: Implications for multi-center studies , 2015, NeuroImage.

[66]  Mike P. Wattjes,et al.  Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin? , 2015, European Radiology.

[67]  Sung-Cheng Huang,et al.  In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging , 2015, Proceedings of the National Academy of Sciences.

[68]  P. Scheltens,et al.  White matter hyperintensities, cognitive impairment and dementia: an update , 2015, Nature Reviews Neurology.

[69]  Philip S. Insel,et al.  Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. , 2015, Brain : a journal of neurology.

[70]  E. Liu,et al.  Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[71]  D. Louis Collins,et al.  The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity , 2015, Alzheimer's & Dementia.

[72]  Sven Haller,et al.  Arterial spin labeling may contribute to the prediction of cognitive deterioration in healthy elderly individuals. , 2015, Radiology.

[73]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[74]  C. Jack,et al.  Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly , 2015, Brain : a journal of neurology.

[75]  G. Zaharchuk,et al.  Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. , 2015, Magnetic resonance in medicine.

[76]  A. Thomas,et al.  Amyloid PET Imaging in Lewy body disorders. , 2015, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[77]  Stefan Klöppel,et al.  Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study. , 2015, Journal of Alzheimer's disease : JAD.

[78]  Bing Chen,et al.  An open science resource for establishing reliability and reproducibility in functional connectomics , 2014, Scientific Data.

[79]  W. Klunk,et al.  Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. , 2014, Brain : a journal of neurology.

[80]  J. Molinuevo,et al.  White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels , 2014, Neurobiology of Aging.

[81]  Nick C Fox,et al.  Imaging endpoints for clinical trials in Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[82]  A. Brickman,et al.  Lobar Microbleeds Are Associated with a Decline in Executive Functioning in Older Adults , 2014, Cerebrovascular Diseases.

[83]  Keith A. Johnson,et al.  Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. , 2014, JAMA neurology.

[84]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[85]  Aart J. Nederveen,et al.  Inter-Vendor Reproducibility of Pseudo-Continuous Arterial Spin Labeling at 3 Tesla , 2014, PloS one.

[86]  Daniel Rueckert,et al.  Robustness of automated hippocampal volumetry across magnetic resonance field strengths and repeat images , 2014, Alzheimer's & Dementia.

[87]  S. Rombouts,et al.  Resting-state functional MR imaging: a new window to the brain. , 2014, Radiology.

[88]  Martha Brumfield,et al.  Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[89]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[90]  Wiro J Niessen,et al.  Hippocampal shape is predictive for the development of dementia in a normal, elderly population , 2014, Human brain mapping.

[91]  L. Younes,et al.  Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer's disease , 2014, NeuroImage: Clinical.

[92]  Olivier Salvado,et al.  Incidence of cerebral microbleeds in preclinical Alzheimer disease , 2014, Neurology.

[93]  Clifford R. Jack,et al.  Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size , 2014, Neurobiology of Aging.

[94]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[95]  George Jewell,et al.  Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study , 2014, Molecular Psychiatry.

[96]  Sterling C. Johnson,et al.  Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation , 2014, NeuroImage: Clinical.

[97]  Bing Wu,et al.  Intra‐ and interscanner reliability and reproducibility of 3D whole‐brain pseudo‐continuous arterial spin‐labeling MR perfusion at 3T , 2014, Journal of magnetic resonance imaging : JMRI.

[98]  N. Schuff,et al.  Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects☆☆☆ , 2013, NeuroImage: Clinical.

[99]  C. Rowe,et al.  Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. , 2014, Brain : a journal of neurology.

[100]  Nick C Fox,et al.  The G8 Dementia Research Summit—a starter for eight? , 2013, The Lancet.

[101]  C. Rowe,et al.  Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.

[102]  Cindee M. Madison,et al.  Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. , 2013, JAMA neurology.

[103]  Stefan Teipel,et al.  Diffusion tensor imaging to determine effects of antidementive treatment on cerebral structural connectivity in Alzheimer's disease. , 2013, Current pharmaceutical design.

[104]  Frederik Barkhof,et al.  An algorithmic approach to structural imaging in dementia , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[105]  Bradford C. Dickerson,et al.  Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau , 2013, Front. Aging Neurosci..

[106]  A. Fagan,et al.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study , 2013, The Lancet Neurology.

[107]  Carlo Pierpaoli,et al.  A framework for the analysis of phantom data in multicenter diffusion tensor imaging studies , 2013, Human brain mapping.

[108]  Rik Ossenkoppele,et al.  Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations , 2013, The Journal of Nuclear Medicine.

[109]  E. Frankó,et al.  Evaluating Alzheimer’s Disease Progression Using Rate of Regional Hippocampal Atrophy , 2013, PloS one.

[110]  Nick C Fox,et al.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.

[111]  P. Scheltens,et al.  An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion , 2013, American Journal of Neuroradiology.

[112]  Martina Bocchetta,et al.  Imaging markers for Alzheimer disease , 2013, Neurology.

[113]  Olivier Colliot,et al.  Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia? , 2013, Alzheimer's & Dementia.

[114]  P. Dupont,et al.  Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease☆ , 2013, NeuroImage: Clinical.

[115]  Maja A. A. Binnewijzend,et al.  Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. , 2013, Radiology.

[116]  J. Molinuevo,et al.  Donepezil Treatment Stabilizes Functional Connectivity During Resting State and Brain Activity During Memory Encoding in Alzheimer’s Disease , 2013, Journal of clinical psychopharmacology.

[117]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[118]  M. Jorge Cardoso,et al.  Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials , 2013, PloS one.

[119]  P. Vemuri,et al.  Brain β-amyloid load approaches a plateau , 2013, Neurology.

[120]  Francis Eustache,et al.  Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease , 2013, NeuroImage: Clinical.

[121]  A. Joshi,et al.  Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ Study , 2013, Alzheimer's & Dementia.

[122]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[123]  Paul M. Matthews,et al.  Brain Microstructure Reveals Early Abnormalities more than Two Years prior to Clinical Progression from Mild Cognitive Impairment to Alzheimer's Disease , 2013, The Journal of Neuroscience.

[124]  P. Selnes,et al.  Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. , 2013, Journal of Alzheimer's disease : JAD.

[125]  W. Klunk,et al.  Development of positron emission tomography β-amyloid plaque imaging agents. , 2012, Seminars in nuclear medicine.

[126]  Y. Stern.  Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[127]  Daniel Rueckert,et al.  Injury markers predict time to dementia in subjects with MCI and amyloid pathology , 2012, Neurology.

[128]  C. Rowe,et al.  Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults , 2012, Neurology.

[129]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[130]  Susumu Mori,et al.  The Fornix Sign: A Potential Sign for Alzheimer's Disease Based on Diffusion Tensor Imaging , 2012, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[131]  D. Rueckert,et al.  Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI , 2012, Neurobiology of Aging.

[132]  Maja A. A. Binnewijzend,et al.  Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment , 2012, Neurobiology of Aging.

[133]  Henrik Zetterberg,et al.  Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. , 2012, Biomarkers in medicine.

[134]  Lin Zhuang,et al.  Microstructural white matter changes in cognitively normal individuals at risk of amnestic MCI , 2012, Neurology.

[135]  Olivier Salvado,et al.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.

[136]  A. Dale,et al.  Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. , 2012, Archives of neurology.

[137]  J. Ferro,et al.  Brain atrophy accelerates cognitive decline in cerebral small vessel disease , 2012, Neurology.

[138]  Kuncheng Li,et al.  The Baseline and Longitudinal Changes of PCC Connectivity in Mild Cognitive Impairment: A Combined Structure and Resting-State fMRI Study , 2012, PloS one.

[139]  Mark Jenkinson,et al.  Structural MRI changes detectable up to ten years before clinical Alzheimer's disease , 2012, Neurobiology of Aging.

[140]  Nick C Fox,et al.  Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. , 2012, Journal of Alzheimer's disease : JAD.

[141]  Michael I. Miller,et al.  Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[142]  M. Mintun,et al.  Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.

[143]  A. Dale,et al.  Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment , 2012, Neurobiology of Aging.

[144]  Mark E. Schmidt,et al.  Positron Emission Tomography in Alzheimer Disease: Diagnosis and Use as Biomarker Endpoints , 2012 .

[145]  P. Visser,et al.  New MRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. , 2012, Journal of Alzheimer's disease : JAD.

[146]  T. Yen,et al.  Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[147]  Zhijun Zhang,et al.  Aberrant Hippocampal Subregion Networks Associated with the Classifications of aMCI Subjects: A Longitudinal Resting-State Study , 2011, PloS one.

[148]  Janet S. Reddin,et al.  Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease , 2011, Neurology.

[149]  Andrei G. Vlassenko,et al.  Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.

[150]  C. Rowe,et al.  Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias , 2011, The Journal of Nuclear Medicine.

[151]  Nick C. Fox,et al.  Algorithms, atrophy and Alzheimer's disease: Cautionary tales for clinical trials , 2011, NeuroImage.

[152]  Philip S. Insel,et al.  CSF biomarker and PIB-PET–derived beta-amyloid signature predicts metabolic, grey matter and cognitive changes in nondemented subjects , 2011, Alzheimer's & Dementia.

[153]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[154]  Norbert Schuff,et al.  Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. , 2011, Radiology.

[155]  Xing Qiu,et al.  Quantification of accuracy and precision of multi-center DTI measurements: A diffusion phantom and human brain study , 2011, NeuroImage.

[156]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[157]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[158]  R. Killiany,et al.  Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults , 2011, Neurology.

[159]  Yufen Chen,et al.  Test–retest reliability of arterial spin labeling with common labeling strategies , 2011, Journal of magnetic resonance imaging : JMRI.

[160]  Michael D. Greicius,et al.  Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. , 2011, Cerebral cortex.

[161]  N. Mercuri,et al.  Effect of Memantine on Resting State Default Mode Network Activity in Alzheimer’s Disease , 2011, Drugs & aging.

[162]  Cindee M. Madison,et al.  Early 11C-PIB Frames and 18F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLD Patients , 2011, Journal of Nuclear Medicine.

[163]  Wiesje M van der Flier,et al.  Brain microbleeds and Alzheimer's disease: innocent observation or key player? , 2011, Brain : a journal of neurology.

[164]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[165]  Kewei Chen,et al.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.

[166]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[167]  Michael Weiner,et al.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. , 2010, JAMA.

[168]  C. Jack,et al.  Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.

[169]  Charles D. Smith,et al.  Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment , 2010, Neurobiology of Aging.

[170]  Rachel L. Mistur,et al.  Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal , 2010, Neurobiology of Aging.

[171]  F. Jessen,et al.  Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease , 2010, Psychiatry Research: Neuroimaging.

[172]  Michael W. Weiner,et al.  Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative , 2010, NeuroImage.

[173]  Owen Carmichael,et al.  Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[174]  Massimo Filippi,et al.  A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[175]  Wiro J Niessen,et al.  A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. , 2010, Brain : a journal of neurology.

[176]  D. Head,et al.  Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly , 2010, Biological Psychiatry.

[177]  L. Ferrucci,et al.  Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB , 2010, Neurology.

[178]  Christian Windischberger,et al.  Toward discovery science of human brain function , 2010, Proceedings of the National Academy of Sciences.

[179]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[180]  Norbert Schuff,et al.  ASL Perfusion MRI Predicts Cognitive Decline and Conversion From MCI to Dementia , 2010, Alzheimer disease and associated disorders.

[181]  S. de Santi,et al.  Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. , 2010, Journal of Alzheimer's disease : JAD.

[182]  Nick C Fox,et al.  A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease , 2009, Neurology.

[183]  Mark A Mintun,et al.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.

[184]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[185]  Nick C. Fox,et al.  A meta-analysis of hippocampal atrophy rates in Alzheimer's disease , 2009, Neurobiology of Aging.

[186]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[187]  Anders M. Dale,et al.  MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths , 2009, NeuroImage.

[188]  Jeffrey A. Fessler,et al.  Reducing between scanner differences in multi-center PET studies , 2009, NeuroImage.

[189]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[190]  André J. W. van der Kouwe,et al.  Reliability of MRI-derived cortical and subcortical morphometric measures: Effects of pulse sequence, voxel geometry, and parallel imaging , 2009, NeuroImage.

[191]  Susan M Resnick,et al.  Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern? , 2008, Journal of Nuclear Medicine.

[192]  Chris Frost,et al.  Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run‐in period increase efficiency? , 2008, Statistics in medicine.

[193]  Nelleke Tolboom,et al.  Simplified parametric methods for [11C]PIB studies , 2008, NeuroImage.

[194]  Oscar L. Lopez,et al.  Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease , 2008, Alzheimer's & Dementia.

[195]  S. Santi,et al.  Hippocampal hypometabolism predicts cognitive decline from normal aging , 2008, Neurobiology of Aging.

[196]  P. Sachdev,et al.  Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review , 2008, Current opinion in neurology.

[197]  W. M. van der Flier,et al.  The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia , 2007, Stroke.

[198]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[199]  F. Schmitt,et al.  Brain structural alterations before mild cognitive impairment , 2007, Neurology.

[200]  Martin Rossor,et al.  Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration. , 2006, Archives of neurology.

[201]  A. Hofman,et al.  Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. , 2006, Archives of general psychiatry.

[202]  Nick C Fox,et al.  Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. , 2005, Archives of neurology.

[203]  S. Leurgans,et al.  MRI predictors of risk of incident Alzheimer disease , 2005, Neurology.

[204]  Michael I. Miller,et al.  Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly , 2005, NeuroImage.

[205]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[206]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[207]  Frederik Barkhof,et al.  Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia: An Interobserver Study , 2003, Stroke.

[208]  P. Scheltens,et al.  A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.

[209]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[210]  H. Braak,et al.  Evolution of the neuropathology of Alzheimer's disease , 1996, Acta neurologica Scandinavica. Supplementum.

[211]  A. Alavi,et al.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. , 1987, AJR. American journal of roentgenology.